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Abstract Arylboronate esters bearing methyl groups in both of 
their ortho positions were stably incorporated into lipid 
membranes at high concentrations without undergoing hydrolysis 
to the corresponding boronic acids. This method could be used in 
combination with previous methods to increase the maximum ratio 
of boron atoms in liposomal boron carriers. 
Boron neutron capture therapy (BNCT) is based on the nuclear 
capture and fission reactions that occur when a non-radioactive 10B 
atom is irradiated with low-energy thermal neutrons, resulting in the 
formation of excited 11B*. This excited material subsequently 
decomposes to yield high energy alpha particles (4He) and 7Li nuclei 
via a linear energy transfer process.1,2 Both of these particles can only 
travel very short distances (5–14 μm), and therefore only exhibit 
damaging effects within the immediate vicinity of the reaction, 
leading to highly selective, single-cell damaging events. The 
development of efficient boron carrier systems capable of delivering 
sufficient concentrations of boron to tumour cells to achieve effective 
BNCT is therefore highly desirable. Liposomal boron carriers have 
been studied extensively as efficient boron delivery systems in 
BNCT.3–12 Although lipids generally exhibit low toxicity, high lipid 
doses can lead to liver toxicity as a result of saturating the lipid uptake 
mechanisms. To reduce the total lipid dose associated with the 
liposomal delivery systems used in BNCT, there is an urgent need for 
the development of liposomes with higher boron contents [i.e., a 
higher boron/phosphorous concentration (B/P) ratio]. Two strategies 
have been investigated to date for the preparation of liposomal boron 
systems, including (i) the introduction of water-soluble boron 
compounds to liposomes via an internal water phase (Scheme 1A);3–5 
and (ii) the use of amphiphilic boron compounds embedded in a 
liposomal bilayer (Scheme 1B).6–8 Recent developments in this area 
have made it possible to reduce the total lipid dose used in liposomal 
delivery systems based on a combination of these two methods; 
however, these systems are only capable of a B/P value of 3.6, which 
is unsatisfactory for BNCT.9–12 According to the latter of the two 
methods described above, the boron atoms would exist on the surface 
of the lipid membranes, where they would behave in the same way as 
the hydrophilic head groups of the lipids. To the best of our knowledge, 
however, there have been no reports in the literature pertaining to the 
attachment of boron atoms to the inside portion of hydrophobic lipid 
membranes (Scheme 1C). The development of a new method for the 
stable incorporation of boron-containing moieties in hydrophobic 
lipid membranes would therefore represent a valuable addition to the 
two methods described above. Furthermore, all three of these methods 
could be used in combination to develop highly efficient liposomal 
delivery systems for BNCT. 
 
Scheme 1 Three methods for preparing liposomal boron carriers, including 
(A) the introduction of water-soluble boron compounds to an internal water 
phase; (B) embedding amphiphilic boron compounds in a liposomal bilayer; 
and (C) incorporating arylboronate esters into the hydrophilic portion of lipid 
membranes. 
B OO B OO
2
CH3(CH2)n O
O
OCH3(CH2)n
O
O P
O
O
O-
N+ Me
Me
MeR1 R1
1: R1 = H
3: R1 = CH3
B OHHO
4: R1 = H
5: R1 = CH3
R1 R1
DMPC:
DPPC:
n = 12
n = 14
 
We recently demonstrated that small hydrophobic -conjugated 
molecules such as fullerenes, porphyrin, azobenzene and pyrenes 
could be incorporated into liposomes without using a chemical 
modification process to provide the necessary affinity for the lipid 
membranes.13–20 These lipid membrane-incorporated guest molecules 
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(LMIG) were found to be stable in aqueous solution for up to 1 month. 
Based on the stability of these systems, it was envisaged that 
hydrophobic arylboronate esters could be used not to destabilise 
liposomes and we consequently evaluated the possibility of using this 
process as a third method for the preparation of liposomal boron 
systems (Scheme 1C). 
We selected the pinacolato boronate ester group as a suitable 
boronate ester for this study, because of the known stability this group 
toward hydrolysis in water. Lipid-membrane-incorporated 
compounds 1‒3 (LMI1‒3), consisting of 1,2-dimyristoyl-sn-glycero-
3-phosphocholine (DMPC), were prepared using a previously 
published premixing method by dissolving lipids and compounds 1‒
3 in chloroform followed by concentration and extraction with water 
(Scheme S1).20,21 The solubilities of 1‒3 in the liposomes were 
determined based on the absorbance characteristics of [1‒3]/[DMPC] 
at 218, 279 and 275 nm, respectively, after subtracting the scattering 
derived from the DMPC liposomes (Fig. 1). The dashed lines in the 
insets of Fig. 1 show the extrapolated absorbance values 
corresponding to 100% of the guests being dissolved in water. 
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Fig. 1 Absorbance values (Abs) at max versus [1, 2 or 3]/[DMPC or DPPC] 
in (A) LMI1 (DMPC), (B) LMI2 (DMPC), (C) LMI3 (DMPC) and (D) LMI3 
(DPPC). The λmax values for LMI1‒3 were 218, 279 and 278 nm, 
respectively. All of the absorption spectra were obtained by subtracting the 
light scattering signals of the DMPC liposomes and were measured at 25 °C 
(1 mm cell, D2O). 
We examined the possibility of incorporating 4,4,5,5-tetramethyl-
2-phenyl-1,3,2-dioxaborolane (1) into liposomes. This compound was 
selected as a model system because it represents the simplest possible 
π structure bearing a boronate ester. The absorbance of LMI1 until 
[1]/[DMPC] = 300 mol% lay on the extrapolated line and was very 
similar to that of bare 1 in hexane (Figs. S1A, S1B and 1A). 
Consequently, 1 in LMI1 was expected to exist in an isolated (i.e., 
disaggregated) state. This result suggested that the lipid affinity of 1 
was very high. We subsequently investigated the effect of the aryl 
moiety on the affinity toward the lipid membranes by preparing lipid-
membrane-incorporated 4,4,5,5-tetramethyl-2-(naphthalen-2-yl)-
1,3,2-dioxaborolane (2) (LMI2) bearing a naphthyl moiety. In the 
range of [2]/[DMPC] = 0–25 mol%, LMI2 exhibited sharp absorption 
in the range of 250–400 nm. Furthermore, a plot showing λmax (279 
nm) versus [2]/[DMPC] for LMI2 gave a straight line (Figs. S1C and 
1B), which indicated that 2 existed in an isolated state within the lipid 
membrane. However, the absorbance of LMI2 reached saturation 
above 50 mol% and the maximum ratio of [2]/[DMPC] was 
determined to be 25 mol%, which was much lower than that of 
[1]/[DMPC], indicating that the introduction of a naphthyl group led 
to a decrease in the affinity of the boronate ester for the lipid 
membranes. 
1H NMR analysis was conducted to confirm the formation of 
LMI1 (Fig. 2). Several peaks were observed at δH = 7.17–7.61 and 
7.76 ppm in the 1H NMR spectrum of LMI1 (red and blue circles in 
Fig. 2B). If all of the available 1 was incorporated into the lipid 
membranes, then there would be no peaks corresponding to 1 in the 
spectrum because of the extreme broadening of the signals after its 
incorporation into the liposomes (Fig. 2B, [1]/[DMPC] = 100 mol%). 
The peaks observed in the spectrum were attributed to phenylboronic 
acid (4), which was formed by the hydrolysis of 1 (based on the peak 
observed at δH = 1.20 ppm, which was assigned to pinacol, Fig. 2B 
and 2C, green circles). Compound 1 was completely converted to 
compound 4 after one week at ambient temperature, based on the 
disappearance of the peak corresponding to the methyl protons of 1 at 
δH = 1.33 ppm (Fig. 2C, green circles). Although the 1H NMR 
spectrum of compound 1 in the absence of liposomes contained 
several sharp peaks (Fig. 2A, blue circles), these peaks broadened 
considerably in the presence of liposomes (Fig. 2B and 2C, blue 
circles). There are two possible explanations for this behaviour, 
including (i) comparable exchange rates for the complexation-
decomplexation of 4 with the liposomes on the 1H NMR time scale; 
and (ii) the incorporation of 4 into small lipid aggregates. We 
evaluated both of these possibilities by measuring the 1H NMR spectra 
of a mixture of DMPC liposomes containing high concentrations of 4. 
The separation of the peaks between free 4 and 4 complexed with the 
liposomes did not occur as shown in Fig. 2D (blue circles). 
Furthermore, because the peak intensities of the small aggregates were 
very small in the range of 0.8‒1.4 ppm compared with those of 4 (Fig. 
2D, black circles), we therefore disproved that most of the molecules 
of 4 were incorporated in small lipid aggregates, as indicated in 
explanation (ii). These results therefore supported explanation (i), 
suggesting that the deprotection of 1 resulted in the formation of 4, 
which was released from the liposomes to exist in an equilibrium 
between the bulk water and the liposomes (Scheme 2B). 
To avoid the hydrolysis of the pinacolato boronate ester in 1, we 
prepared lipid-membrane-incorporated 2-(2,6-dimethylphenyl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3) (LMI3) bearing a methyl 
group at both of the ortho positions of the phenyl ring.22 As shown in 
Figs. S1D and 1C, the absorbance values of LMI3 were consistent 
with the extrapolated lines for concentrations of less than 150 mol%, 
but deviated from the lines at a concentration of 200 mol%. Given that 
no precipitation was observed in any of these samples of LMI3, this 
deviation was attributed to free compound 3, which was not 
incorporated into the liposomes at concentration greater than 150 
mol%. This material was subsequently removed by filtration through 
the membranes (pore size 50 nm) during the extrusion process. 
Compound 3 dissolved in water in the presence of the DMPC 
liposomes at a concentration of [3]/[DMPC] = 150 mol%, making it 
possible to confirm the formation of LMI3 by 1H NMR analysis at 100 
mol% (Fig. 3B). The 1H NMR spectrum of LMI3 did not contain any 
peaks belonging to 2,6-dimethylphenylboronic acid (5) or the pinacol 
formed by the hydrolysis of 3 (Fig. 3A and 3B, blue circles). This 
result clearly demonstrated that 3 was not being hydrolysed in water. 
However, because broad peaks were observed in the range of 0.8‒1.4 
ppm for LMI3, compound 3 was adjudged to have destabilised the 
DMPC liposomes to a much greater extent than compound 1 (Fig. 3B, 
black circles). If the DMPC liposomes remained as large hollow 
particles with a diameter greater than 70 nm, then we wouldn’t expect 
to see any broad peaks in the range of 0.8‒1.4 ppm because of the 
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extreme broadening of the signals.20 These results therefore suggest 
that some of the DMPC lipids formed small self-aggregates with 3 
(Scheme 2C). Although we were unable to accurately calculate the 
peak intensities of DMPC because of considerable peak broadening,  
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Fig. 2 1H NMR spectra (400 MHz, D2O, 25 °C) of (A) a mixture of 4 and 
pinacol ([4] = [pinacol] = 13.0 mM), LMI1 (B) immediately and (C) one week 
after its preparation ([1]/[DMPC] = 100.0 mol%, [DMSO] = 0.4 mM), and (D) 
a mixture of liposome and 4 [4]/[DMPC] = 300 mol%. ([DMPC] = 2.0 mM, 
[DMSO] = 0.4 mM). (●: 1, ●: 4, ●: pinacol, ●: DMPC lipid in the small 
aggregates and ○: DMSO). 
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Fig. 3 1H NMR spectra (400 MHz, D2O, 25 °C) of (A) a mixture of 5 and 
pinacol ([5] = [pinacol] = 11.0 mM), LMI3 consisting of DMPC (B) 
immediately and (C) 1 week after its preparation ([3]/[DMPC] = 100 mol%, 
[DMPC] = 2.0 mM and [DMSO] = 0.4 mM), and (D) LMI3 consisting of DPPC 
([3]/[DPPC] = 100 mol%, [DPPC] = 2.0 mM and [DMSO] = 0.4 mM) (●: 3, ●: 
5, ●: pinacol, ●: DMPC or DPPC lipid in the small aggregates and ○: DMSO). 
the percentage of DMPC in the small aggregates was estimated to be 
approximately 20% of all the DMPC. The leakage percentage of 3 was 
determined to be 14% based on the peak intensities of 3 relative to 
DMSO, which was adopted as an internal standard (Fig. 3B, [DMSO] 
= 0.4 mM). Fig. 3C shows that the molecules of 3 in the liposomes 
were stable for one week at ambient temperature, as evidenced by the 
lack of any peaks corresponding to 2,6-dimethylphenylboronic acid 
(5) or pinacol. It is suggested that the reason for the stability of 3 is 
that the methyl groups in both of the ortho positions of the phenyl ring 
and in pinacol protect the boronate ester against attack by water (Fig. 
S4). 
To inhibit the formation of the small aggregates, we prepared 
LMI3 consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC), which has been reported to form much more stable liposomes 
than DMPC. Fig. 3D shows that the intensities of the broadened peaks 
observed by 1H NMR in the range of 0.8‒1.4 ppm dramatically 
decreased in the presence of DPPC compared with those observed in 
the in presence of DMPC (Fig. 3B). The broad peaks at 1.4, 2.4 and 
7.0 ppm were assigned to molecules of 3 encapsulated in the small 
partially formed aggregates (Fig. 3D, red mark, Scheme 2C). The 
leakage percentage of 3 was determined to be 4% based on the peak 
intensities of 3 relative to DMSO. The absorbance values of LMI3 
consisting of DPPC reached saturation levels above 125 mol% and the 
maximum ratio of [3]/[DPPC] (100 mol%) was found to be much 
lower than that of [3]/[DMPC] (Figs. S1E and 1D). 
  
Scheme  2  Schematic  illustration  of  (A)  stable  LMIG  [category  (i)],  (B)  the 
dissolution of the guest molecules released from LMIG in water [category (ii)] and 
(C) the formation of small aggregates between the guest molecules released from 
LMIG and the lipids [category (iii)]. 
In summary, although compound 1 was effectively incorporated 
into liposomes in water, its pinacolato boronate ester moiety was 
partially hydrolysed to give phenylboronic acid (4), which was 
released from the lipid membrane. The hydrolysis of the boronate 
ester was inhibited using 3, which was prepared as the 2,6-
dimethylated analogue of 1. Compound 3 was found to be stable in 
the liposomes for one week at ambient temperature. However, some 
of the molecules of 3 formed small aggregates such as micelles or very 
small liposomes with the lipids. The formation of these small 
aggregates was appreciably inhibited using DPPC. The B/P value is 
approximately 1.0 ([3]/[DPPC] = 100 mol%) and is not particularly 
high. However, it is envisaged that this method could be used in 
combination with two previously published methods to increase the 
maximum ratio of boron atoms in liposomal boron carriers, as shown 
in Scheme 1. There is therefore an urgent need to identify suitable 
derivatives of 3 that would be capable of forming stable liposomes at 
a high concentration. 
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